| Name | Title | Contact Details |
|---|
ContraVir is a biopharmaceutical company focused primarily on the development of drugs to treat herpes zoster, or shingles, which is an infection caused by the reactivation of varicella zoster virus or VZV. Our lead candidate, FV-100, is an orally available nucleoside analogue prodrug of CF-1743 that we are developing for the treatment of shingles. Published preclinical studies demonstrate that FV-100 is significantly more potent against VZV than acyclovir, valacyclovir, and famciclovir, the FDA-approved drugs used for the treatment of shingles. Preclinical studies further demonstrate that FV-100 has a more rapid onset of antiviral activity, and may fully inhibit the replication of VZV more rapidly than these drugs at significantly lower concentration levels. In addition, pharmacokinetic data from completed phase 1 and 2 clinical trials suggest that FV-100 has the potential to demonstrate antiviral activity when dosed orally once-a-day at significantly lower levels than valacyclovir, acyclovir, and famciclovir.
Health Choice Network (HCN) is a national model of a successful collaboration of community health centers (CHCs) and one of several HRSA-sponsored Health Center Controlled Networks. HCN is addressing health care disparities, providing health information technologies and strengthening the financial position of the community health care system. Founded in 1994 as a 501c(3) organization, HCN was created and is governed by its members who comprise a minority-based Board of Directors. Network members maintain their vital community orientation by retaining their local-governing, consumer-majority Boards of Directors. Community Health Centers that own and control the Network operate more efficiently, can deliver care more effectively and are working together to care for more patients.
Before Brands is a health and wellness company that is developing a series of products targeted at transforming the world`s relationship with food allergies. The science behind each of our products is our proprietary Early Adaptive Training (E.A.T.) protein blend that was developed at Stanford University by a pediatrician, allergist and Mother of five.
JW Nutritional strives to maintain a high quality of business from communication all the way to product fulfillment to ensure the success of our clients.
Enzymatic Therapy, Inc. is a high performance organization, focusing on both results and behavior to achieve our business goals.